200 related articles for article (PubMed ID: 10049714)
1. Dopamine D4-like binding sites labeled by [3H]nemonapride include substantial serotonin 5-HT2A receptors in primate cerebral cortex.
Noda-Saita K; Matsumoto M; Hidaka K; Hatanaka K; Ohmori J; Okada M; Yamaguchi T
Biochem Biophys Res Commun; 1999 Feb; 255(2):367-70. PubMed ID: 10049714
[TBL] [Abstract][Full Text] [Related]
2. Multiple [3H]-nemonapride binding sites in calf brain.
Helmeste DM; Tang SW; Li M; Fang H
Naunyn Schmiedebergs Arch Pharmacol; 1997 Jul; 356(1):17-21. PubMed ID: 9228185
[TBL] [Abstract][Full Text] [Related]
3. Differential labeling of dopamine and sigma sites by [3H]nemonapride and [3H]raclopride in postmortem human brains.
Tang SW; Helmeste DM; Fang H; Li M; Vu R; Bunney W; Potkin S; Jones EG
Brain Res; 1997 Aug; 765(1):7-12. PubMed ID: 9310388
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors.
Hidaka K; Matsumoto M; Tada S; Tasaki Y; Yamaguchi T
Neurosci Lett; 1995 Feb; 186(2-3):145-8. PubMed ID: 7777184
[TBL] [Abstract][Full Text] [Related]
5. Brain sigma receptors labelled by [3H]nemonapride.
Helmeste D; Tang SW; Fang H; Li M
Eur J Pharmacol; 1996 Apr; 301(1-3):R1-3. PubMed ID: 8773467
[TBL] [Abstract][Full Text] [Related]
6. Regional distribution of dopamine D4 receptors in rat forebrain.
Tarazi FI; Kula NS; Baldessarini RJ
Neuroreport; 1997 Nov; 8(16):3423-6. PubMed ID: 9427299
[TBL] [Abstract][Full Text] [Related]
7. II. Localization and characterization of dopamine D4 binding sites in rat and human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1.
Primus RJ; Thurkauf A; Xu J; Yevich E; McInerney S; Shaw K; Tallman JF; Gallagher DW
J Pharmacol Exp Ther; 1997 Aug; 282(2):1020-7. PubMed ID: 9262371
[TBL] [Abstract][Full Text] [Related]
8. Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride.
Seeman P; Van Tol HH
J Neurochem; 1995 Mar; 64(3):1413-5. PubMed ID: 7861175
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of S(+)N-n-propylnorapomorphine compared with typical and atypical antipsychotics: differential increases of cerebrocortical D2-like and striatolimbic D4-like dopamine receptors.
Tarazi FI; Yeghiayan SK; Baldessarini RJ; Kula NS; Neumeyer JL
Neuropsychopharmacology; 1997 Sep; 17(3):186-96. PubMed ID: 9272485
[TBL] [Abstract][Full Text] [Related]
10. The binding of both [3H]nemonapride and [3H]raclopride is increased in schizophrenia.
Marzella PL; Hill C; Keks N; Singh B; Copolov D
Biol Psychiatry; 1997 Oct; 42(8):648-54. PubMed ID: 9325557
[TBL] [Abstract][Full Text] [Related]
11. In vitro pharmacological profile of YM-43611, a novel D2-like receptor antagonist with high affinity and selectivity for dopamine D3 and D4 receptors.
Hidaka K; Tada S; Matsumoto M; Ohmori J; Tasaki Y; Nomura T; Usuda S; Yamaguchi T
Br J Pharmacol; 1996 Apr; 117(8):1625-32. PubMed ID: 8732269
[TBL] [Abstract][Full Text] [Related]
12. [3H]MDL 100,907 labels 5-HT2A serotonin receptors selectively in primate brain.
López-Giménez JF; Vilaró MT; Palacios JM; Mengod G
Neuropharmacology; 1998 Sep; 37(9):1147-58. PubMed ID: 9833645
[TBL] [Abstract][Full Text] [Related]
13. [3H]nemonapride binding in human caudate and putamen.
Marzella PL; Copolov D
Brain Res Bull; 1997; 44(2):167-70. PubMed ID: 9292206
[TBL] [Abstract][Full Text] [Related]
14. Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride.
Seeman P; Guan HC; Van Tol HH
Eur J Pharmacol; 1995 Nov; 286(2):R3-5. PubMed ID: 8605946
[TBL] [Abstract][Full Text] [Related]
15. Differential in vivo inhibition of [3H]nemonapride binding by atypical antipsychotics in rat striatum, olfactory lobes, and frontal cortex.
Assié MB; Consul-Denjean N; Koek W; Newman-Tancredi A
Pharmacology; 2005 Oct; 75(2):63-8. PubMed ID: 16020947
[TBL] [Abstract][Full Text] [Related]
16. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
Florijn WJ; Tarazi FI; Creese I
J Pharmacol Exp Ther; 1997 Feb; 280(2):561-9. PubMed ID: 9023264
[TBL] [Abstract][Full Text] [Related]
17. Quantitative analysis of the dopamine D4 receptor in the mouse brain.
Defagot MC; Falzone TL; Low MJ; Grandy DK; Rubinstein M; Antonelli MC
J Neurosci Res; 2000 Jan; 59(2):202-8. PubMed ID: 10650878
[TBL] [Abstract][Full Text] [Related]
18. [3H]nemonapride and [3H]spiperone label equivalent numbers of D2 and D3 dopamine receptors in a range of tissues and under different conditions.
Vile JM; D'Souza UM; Strange PG
J Neurochem; 1995 Feb; 64(2):940-3. PubMed ID: 7830089
[TBL] [Abstract][Full Text] [Related]
19. The naphtosultam derivative RP 62203 (fananserin) has high affinity for the dopamine D4 receptor.
Heuillet E; Petitet F; Mignani S; Malleron JL; Lavayre J; Néliat G; Doble A; Blanchard JC
Eur J Pharmacol; 1996 Oct; 314(1-2):229-33. PubMed ID: 8957240
[TBL] [Abstract][Full Text] [Related]
20. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand.
Seeman P; Van Tol HH
Eur J Pharmacol; 1995 Oct; 291(2):59-66. PubMed ID: 8566176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
